Literature DB >> 19956194

Prostate cancer: Androgen deprivation therapy and bone loss.

Eitan Amir, Ian F Tannock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19956194     DOI： 10.1038/nrurol.2009.218

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Authors:  Susan L Greenspan; Joel B Nelson; Donald L Trump; Neil M Resnick
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

2.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

3.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

Review 4.  Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

Authors:  D A Galvão; D R Taaffe; N Spry; R U Newton
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-05-08       Impact factor: 5.554

5.  A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Authors:  Jean-Jacques Body; Thierry Facon; Robert E Coleman; Allan Lipton; Filip Geurs; Michelle Fan; Donna Holloway; Mark C Peterson; Pirow J Bekker
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

6.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

7.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

Review 8.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Authors:  E Seeman
Journal:  Bone       Date:  2007-06-26       Impact factor: 4.398
  8 in total
  1 in total

Review 1.  The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.

Authors:  Sourik S Ganguly; Xiaohong Li; Cindy K Miranti
Journal:  Front Oncol       Date:  2014-12-15       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.